Premium
Cross‐Reactive Skin Eruption with Both Carbamazepine and Oxcarbazepine
Author(s) -
Beran Roy G.
Publication year - 1993
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/j.1528-1157.1993.tb02392.x
Subject(s) - oxcarbazepine , carbamazepine , anticonvulsant , prodrug , medicine , epilepsy , pharmacology , dermatology , skin reaction , derivative (finance) , anesthesia , psychiatry , financial economics , economics
Summary: Oxcarbazepine (OCBZ), a 10‐keto derivative of carbamazepine (CBZ) has been reported to have a similar range of efficacy and fewer unwanted effects than CBZ since it is a prodrug for the monohydroxy derivative (MHD). A cross‐reactivity of only 1 in 4 has been reported between OCBZ and CBZ. For these reasons, we tried OCBZ with 3 consecutive patients with poorly controlled epilepsy who had had a therapeutic response to CBZ but in whom CBZ was discontinued because of serious skin reaction. Each patient had a similar skin response after exposure to only 600–900 mg OCBZ, which suggests a need to practice caution when substituting OCBZ for CBZ in patients known to have serious skin reaction to CBZ.